Luca Benatti / Chief Executive Officer
Dr Luca Benatti is the Chief Executive Officer since June 2012. He has 27 year experience in Pharma and Biotech. He was Co-founder, CEO and Member of the Board of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies, with most advanced compound safinamide now approaching worldwide regulatory filing for the treatment of Parkinson's disease. During his tenure, Newron raised significant capital from international venture capital firms, and was listed at the Swiss stock exchange. He also was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon, and in the acquisition of the UK biotech Company Hunter Fleming. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Newron (Swiss Stock Exchange), Intercept Pharmaceuticals (Nasdaq), Chairman of the Scientific Advisory Board of Zambon, Vice President and member of the Board of Assobiotec and member of the Jury of the European Biotechnica Award. He has authored several scientific publications and holds numerous patents.
Mauro Magnani / Chief Scientific Officer
Prof. Mauro Magnani is the Company co-founder and Chief Scientific Officer and Director since 2007. He is Professor of Biochemistry and Director of the Centre of Biotechnology, at the University of Urbino, Italy.
Prof. Magnani is an international leader in the development of drug delivery technologies using red blood cells. During his academic career he has been: Visiting Researcher, Dept. Biochemistry, Univ. Birmingham, 1980; Visiting Prof. Dept. Biology, Haifa, Israel. Since 1986 he is Full Professor of Biochemistry ; Dean, Faculty of Sciences University of Urbino 1995-2001; Director Interuniversity Consortium for Biotechnology (CIB) 1998-2004; Vice Rector of the University of Urbino 2001-2009. He is also a "Technical Director" nominated by the "Agenzia Italiana del Farmaco, AIFA" with n. AIDT-19/2005. Co-founder of various start-up companies, and author of more than 400 papers published in international refereed scientific journals and inventor of numerous patents; Co-editor of three books and reviewer for over 30 international Journals.
Antonio Ferrari / Global Medical Director
Dr Antonio Ferrari, MD, is the Global Medical Director since December 2015. He brings more than 15 years of experience in clinical development and medical affairs. Prior to joining EryDel, he was involved in global responsibilities in Serono, Shire and Chiesi Farmaceutici, in area such as: rare disease, neurology, endocrinology, diabetes, obesity, infertility, respiratory, hypertension, thrombosis, cardiology and translational medicine. He has been the Clinical Program Leader for regulatory and clinical development in the US for Chiesi. In the last 6 years he and his team obtained approval of various drugs in China, including fast track, and in other Asian and ex-Eu countries. Antonio also has 14 years of clinical experience in clinical cardiology and internal medicine working as Medical Manager and Head of Unit at Policlinico San Matteo in Pavia., Italy. He specialized in cardiology and internal medicine with a PhD in internal medicine and cronobiology. Antonio received a Pharma MBA and was former associate professor at Pavia University. He is co-founder of numerous scientific papers.
Giovanni Mambrini / Director Medical Device
Dr Giovanni Mambrini is Director of Medical Devices, R&D and Operations since June 2012 and he has also responsibility on Quality System and Regulatory Affairs of Medical Devices. EryDel's General Manager from 2008 to May 2012, he has highly contributed to develop the Company. He has 15 year experience in medical device technologies within multinational Companies and gained a deep experience in blood related innovative devices.
Prior to joining EryDel, he was Manager of R&D at Covidien (from 1998 to 2002), Scientific Affair Manager at Dideco (from 2002 to 2005); Leader of "Biocompatibility & Biosensors, Centre for Innovation and Technological Excellence" at Sorin Group Italia (from 2005 to 2008).